Evaluation and Assessment of the Radio-Peptide Treatment Efficacy

Abstract

The criteria settled for the evaluation of therapy response in solid tumors, i.e., those (a) of the World Health Organization (WHO, Miller et al. 1981), (b) the (RECIST criteria, Therasse et al. 2000), (c) the criteria of the European Association for the Study of the Liver (EASL, Bruix et al. 2001), (d) the new RECIST criteria (RECIST 1.1, Eisenhauer et al. 2009), and (e) the modified RECIST criteria (mRECIST, Lencioni and Llovet 2010) standardize regular measurement methods for converting image observations (CT or MRI) into a quantitative and statistically controllable framework that assesses the response of tumor to treatment. Eventhough the WHO criteria were first developed for radiography, CT, and MRI, they were modified into RECIST, RECICT 1.1 and mRECIST to formulate measurements more process-consistent. In consequence, a plethora of methods were developed to cover corresponding necessities derived from the several imaging technologies. Each method uses a pragmatically simplified technique that depends on the observer’s assessment of lesion limits. The chapter describes the most prominent response evaluation criteria not only used in neuroendocrine tumors but in every solid malignancy.